Protection against Tetanus and Diphtheria in Europe: The impact of age, gender and country of origin based on data from the MARK-AGE Study

Birgit Weinberger, Michael Keller, Christina Putzer, Daniel Breitenberger, Bernhard Koller, Simone Fiegl, María Moreno-Villanueva, Jürgen Bernhardt, Claudio Franceschi, Konstantinos Voutetakis, Efstathios S. Gonos, Mikko Hurme, Ewa Sikora, Olivier Toussaint, Florence Debacq-Chainiaux, Tilman Grune, Nicolle Breusing, Alexander Bürkle, Beatrix Grubeck-Loebenstein

Résultats de recherche: Contribution à un journal/une revueArticle

Résumé

Due to the successful implementation of vaccination strategies early-life morbidity and mortality due to infectious disease has been reduced dramatically. Vaccines against tetanus and diphtheria are among the most frequently used vaccines worldwide, but various studies in different European countries have shown that protection against tetanus and particularly against diphtheria is unsatisfactory in adults and older persons. In this study we analyzed tetanus- and diphtheria-specific antibody concentrations in 2100 adults of different age from 6 selected European countries (Austria, Belgium, Germany, Greece, Italy, Poland) in order to investigate differences in the level of protection against tetanus and diphtheria across Europe. Our data reveal that tetanus- and diphtheria-specific antibody concentrations vary greatly between countries, which is also reflected in the percentage of persons with antibody concentrations below the protective level (0.1 IU/ml), which ranged from 2 to 31% percent for tetanus and 28–63% for diphtheria. In most countries, tetanus- and diphtheria-specific antibody concentrations decrease with age. This phenomenon is more pronounced in countries with generally low antibody levels, such as Italy, Poland and Greece. Interestingly, tetanus-specific antibody concentrations are generally higher in males than in females, which is probably due to vaccination during their military service or more frequent booster vaccinations after injuries, whereas no gender-related differences were found for diphtheria-specific antibodies. In conclusion, our study demonstrates that the European population is not fully protected against tetanus and diphtheria. Measures to improve protection should include a life-long perspective on vaccination, more education to increase awareness of and compliance with vaccination guidelines, and a harmonization of recommendations and incentives across Europe.

langue originaleAnglais
Pages (de - à)109-112
Nombre de pages4
journalExperimental Gerontology
Volume105
Les DOIs
étatPublié - 1 mai 2018

Empreinte digitale

Diphtheria
Tetanus
Antibodies
Vaccination
Greece
Poland
Italy
Vaccines
Diphtheria-Tetanus Vaccine
Austria
Belgium
Communicable Diseases
Germany
Education
Motivation
Guidelines
Morbidity
Mortality
Wounds and Injuries

Citer ceci

Weinberger, Birgit ; Keller, Michael ; Putzer, Christina ; Breitenberger, Daniel ; Koller, Bernhard ; Fiegl, Simone ; Moreno-Villanueva, María ; Bernhardt, Jürgen ; Franceschi, Claudio ; Voutetakis, Konstantinos ; Gonos, Efstathios S. ; Hurme, Mikko ; Sikora, Ewa ; Toussaint, Olivier ; Debacq-Chainiaux, Florence ; Grune, Tilman ; Breusing, Nicolle ; Bürkle, Alexander ; Grubeck-Loebenstein, Beatrix. / Protection against Tetanus and Diphtheria in Europe : The impact of age, gender and country of origin based on data from the MARK-AGE Study. Dans: Experimental Gerontology. 2018 ; Vol 105. p. 109-112.
@article{27421fa4415944b5ab0a5a0a19fdc141,
title = "Protection against Tetanus and Diphtheria in Europe: The impact of age, gender and country of origin based on data from the MARK-AGE Study",
abstract = "Due to the successful implementation of vaccination strategies early-life morbidity and mortality due to infectious disease has been reduced dramatically. Vaccines against tetanus and diphtheria are among the most frequently used vaccines worldwide, but various studies in different European countries have shown that protection against tetanus and particularly against diphtheria is unsatisfactory in adults and older persons. In this study we analyzed tetanus- and diphtheria-specific antibody concentrations in 2100 adults of different age from 6 selected European countries (Austria, Belgium, Germany, Greece, Italy, Poland) in order to investigate differences in the level of protection against tetanus and diphtheria across Europe. Our data reveal that tetanus- and diphtheria-specific antibody concentrations vary greatly between countries, which is also reflected in the percentage of persons with antibody concentrations below the protective level (0.1 IU/ml), which ranged from 2 to 31{\%} percent for tetanus and 28–63{\%} for diphtheria. In most countries, tetanus- and diphtheria-specific antibody concentrations decrease with age. This phenomenon is more pronounced in countries with generally low antibody levels, such as Italy, Poland and Greece. Interestingly, tetanus-specific antibody concentrations are generally higher in males than in females, which is probably due to vaccination during their military service or more frequent booster vaccinations after injuries, whereas no gender-related differences were found for diphtheria-specific antibodies. In conclusion, our study demonstrates that the European population is not fully protected against tetanus and diphtheria. Measures to improve protection should include a life-long perspective on vaccination, more education to increase awareness of and compliance with vaccination guidelines, and a harmonization of recommendations and incentives across Europe.",
keywords = "Antibody concentrations, Diphtheria, Europe, Tetanus, Vaccination",
author = "Birgit Weinberger and Michael Keller and Christina Putzer and Daniel Breitenberger and Bernhard Koller and Simone Fiegl and Mar{\'i}a Moreno-Villanueva and J{\"u}rgen Bernhardt and Claudio Franceschi and Konstantinos Voutetakis and Gonos, {Efstathios S.} and Mikko Hurme and Ewa Sikora and Olivier Toussaint and Florence Debacq-Chainiaux and Tilman Grune and Nicolle Breusing and Alexander B{\"u}rkle and Beatrix Grubeck-Loebenstein",
year = "2018",
month = "5",
day = "1",
doi = "10.1016/j.exger.2017.08.037",
language = "English",
volume = "105",
pages = "109--112",
journal = "Experimental Gerontology",
issn = "0531-5565",
publisher = "Elsevier Inc.",

}

Weinberger, B, Keller, M, Putzer, C, Breitenberger, D, Koller, B, Fiegl, S, Moreno-Villanueva, M, Bernhardt, J, Franceschi, C, Voutetakis, K, Gonos, ES, Hurme, M, Sikora, E, Toussaint, O, Debacq-Chainiaux, F, Grune, T, Breusing, N, Bürkle, A & Grubeck-Loebenstein, B 2018, 'Protection against Tetanus and Diphtheria in Europe: The impact of age, gender and country of origin based on data from the MARK-AGE Study', Experimental Gerontology, VOL. 105, p. 109-112. https://doi.org/10.1016/j.exger.2017.08.037

Protection against Tetanus and Diphtheria in Europe : The impact of age, gender and country of origin based on data from the MARK-AGE Study. / Weinberger, Birgit; Keller, Michael; Putzer, Christina; Breitenberger, Daniel; Koller, Bernhard; Fiegl, Simone; Moreno-Villanueva, María; Bernhardt, Jürgen; Franceschi, Claudio; Voutetakis, Konstantinos; Gonos, Efstathios S.; Hurme, Mikko; Sikora, Ewa; Toussaint, Olivier; Debacq-Chainiaux, Florence; Grune, Tilman; Breusing, Nicolle; Bürkle, Alexander; Grubeck-Loebenstein, Beatrix.

Dans: Experimental Gerontology, Vol 105, 01.05.2018, p. 109-112.

Résultats de recherche: Contribution à un journal/une revueArticle

TY - JOUR

T1 - Protection against Tetanus and Diphtheria in Europe

T2 - The impact of age, gender and country of origin based on data from the MARK-AGE Study

AU - Weinberger, Birgit

AU - Keller, Michael

AU - Putzer, Christina

AU - Breitenberger, Daniel

AU - Koller, Bernhard

AU - Fiegl, Simone

AU - Moreno-Villanueva, María

AU - Bernhardt, Jürgen

AU - Franceschi, Claudio

AU - Voutetakis, Konstantinos

AU - Gonos, Efstathios S.

AU - Hurme, Mikko

AU - Sikora, Ewa

AU - Toussaint, Olivier

AU - Debacq-Chainiaux, Florence

AU - Grune, Tilman

AU - Breusing, Nicolle

AU - Bürkle, Alexander

AU - Grubeck-Loebenstein, Beatrix

PY - 2018/5/1

Y1 - 2018/5/1

N2 - Due to the successful implementation of vaccination strategies early-life morbidity and mortality due to infectious disease has been reduced dramatically. Vaccines against tetanus and diphtheria are among the most frequently used vaccines worldwide, but various studies in different European countries have shown that protection against tetanus and particularly against diphtheria is unsatisfactory in adults and older persons. In this study we analyzed tetanus- and diphtheria-specific antibody concentrations in 2100 adults of different age from 6 selected European countries (Austria, Belgium, Germany, Greece, Italy, Poland) in order to investigate differences in the level of protection against tetanus and diphtheria across Europe. Our data reveal that tetanus- and diphtheria-specific antibody concentrations vary greatly between countries, which is also reflected in the percentage of persons with antibody concentrations below the protective level (0.1 IU/ml), which ranged from 2 to 31% percent for tetanus and 28–63% for diphtheria. In most countries, tetanus- and diphtheria-specific antibody concentrations decrease with age. This phenomenon is more pronounced in countries with generally low antibody levels, such as Italy, Poland and Greece. Interestingly, tetanus-specific antibody concentrations are generally higher in males than in females, which is probably due to vaccination during their military service or more frequent booster vaccinations after injuries, whereas no gender-related differences were found for diphtheria-specific antibodies. In conclusion, our study demonstrates that the European population is not fully protected against tetanus and diphtheria. Measures to improve protection should include a life-long perspective on vaccination, more education to increase awareness of and compliance with vaccination guidelines, and a harmonization of recommendations and incentives across Europe.

AB - Due to the successful implementation of vaccination strategies early-life morbidity and mortality due to infectious disease has been reduced dramatically. Vaccines against tetanus and diphtheria are among the most frequently used vaccines worldwide, but various studies in different European countries have shown that protection against tetanus and particularly against diphtheria is unsatisfactory in adults and older persons. In this study we analyzed tetanus- and diphtheria-specific antibody concentrations in 2100 adults of different age from 6 selected European countries (Austria, Belgium, Germany, Greece, Italy, Poland) in order to investigate differences in the level of protection against tetanus and diphtheria across Europe. Our data reveal that tetanus- and diphtheria-specific antibody concentrations vary greatly between countries, which is also reflected in the percentage of persons with antibody concentrations below the protective level (0.1 IU/ml), which ranged from 2 to 31% percent for tetanus and 28–63% for diphtheria. In most countries, tetanus- and diphtheria-specific antibody concentrations decrease with age. This phenomenon is more pronounced in countries with generally low antibody levels, such as Italy, Poland and Greece. Interestingly, tetanus-specific antibody concentrations are generally higher in males than in females, which is probably due to vaccination during their military service or more frequent booster vaccinations after injuries, whereas no gender-related differences were found for diphtheria-specific antibodies. In conclusion, our study demonstrates that the European population is not fully protected against tetanus and diphtheria. Measures to improve protection should include a life-long perspective on vaccination, more education to increase awareness of and compliance with vaccination guidelines, and a harmonization of recommendations and incentives across Europe.

KW - Antibody concentrations

KW - Diphtheria

KW - Europe

KW - Tetanus

KW - Vaccination

UR - http://www.scopus.com/inward/record.url?scp=85031326449&partnerID=8YFLogxK

U2 - 10.1016/j.exger.2017.08.037

DO - 10.1016/j.exger.2017.08.037

M3 - Article

AN - SCOPUS:85031326449

VL - 105

SP - 109

EP - 112

JO - Experimental Gerontology

JF - Experimental Gerontology

SN - 0531-5565

ER -